|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | A01K 67/027 | (2006.01) |
| C07K 14/705 | (2006.01) | ||
| C07K 14/74 | (2006.01) |
| (11) | Number of the document | 3262932 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17184955.7 |
| Date of filing the European patent application | 2012-10-26 | |
| (97) | Date of publication of the European application | 2018-01-03 |
| (45) | Date of publication and mention of the grant of the patent | 2019-05-15 |
| (46) | Date of publication of the claims translation | 2019-08-26 |
| (30) | Number | Date | Country code |
| 201161552587 P | 2011-10-28 | US | |
| 201161552582 P | 2011-10-28 | US | |
| 201261700908 P | 2012-09-14 | US |
| (72) |
MACDONALD, Lynn, US
MURPHY, Andrew J., US
GURER, Cagan, US
MCWHIRTER, John, US
VORONINA, Vera, US
HARRIS, Faith, US
STEVENS, Sean, US
|
| (73) |
Regeneron Pharmaceuticals, Inc.,
777 Old Saw Mill River Road, Tarrytown, NY 10591,
US
|
| (74) |
Jurga PETNIŪNAITĖ,
AAA Law, A. Goštauto g. 40B, Verslo centras "Dvyniai", LT-03163 Vilnius,
LT
|
| (54) | Pelės su genetiškai modifikuotu pagrindiniu histosuderinamumo kompleksu |
| GENETICALLY MODIFIED MAJOR HISTOCOMPATIBILITY COMPLEX MICE |
| Payment date | Validity (years) | Amount | |
| 2024-09-19 | 13 | 289.00 EUR |
| 2025-10-26 |